NEW YORK (GenomeWeb) – JP Morgan has downgraded Genomic Health to Underweight from Neutral, citing a slower than expected coverage expansion for the company's prostate cancer test, and a "tepid" outlook for the company's core breast cancer testing business.

The investment bank also lowered the price target on Genomic Health's stock price to $25 from $28.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.